HIGHLIGHTS
- who: Francesca Ferretti from the Humanitas University, Italy have published the paper: The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study, in the Journal: (JOURNAL) of 08/08/2022
- what: The authors aimed to assess the cumulative incidence and clinical course of EIMs in patients treated with Vedolizumab (VDZ) and non-gut selective biologic drugs. The aims of IBD medical treatment are the induction and maintenance of clinical and endoscopic remission to treat symptoms, guarantee an improved quality of life, and prevent complications leading to hospital admission and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.